Stalevo anvendes hos patienter, der behandles med en kombination af levodopa og en dopa- decarboxylasehæmmer (to standardlægemidler mod Parkinsons sygdom), hos hvem der hen mod slutningen af perioden mellem to doser af medicinen kommer "fluktuationer", som ikke kan behandles med standardkombinationen alene.
Stalevo is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson’ s disease) but are having ‘ fluctuations’ towards the end of the period between two doses of their medication that cannot be treated with the standard combination alone.